Marie Rosenthal, MS

A closer look at the hematology pipeline where there are multiple promising studies in progress for hematologic malignancies, including lymphoma, leukemia, and multiple myeloma.

Economic pressures are forcing many oncologists to leave small private practices for larger institutional organizations.

With the recent consideration of the 2010 Affordable Care Act by the US Supreme Court, the rising costs of healthcare have appeared, once again, on our radar screens.

Before the oncology treatment paradigm can move from a one-size-fits-all model to true personalized medicine, the medical establishment must find a cost-effective way to identify biomarkers.

Shrinking reimbursements and higher healthcare costs are making it difficult for community oncologists to stay in practice.

The development of crizotinib has helped crystallize a relatively rare molecular subset of NSCLC and holds the potential for wider use in treating patients with the disease.

Two novel treatments for advanced melanoma, ipilimumab (Yervoy) and vemurafenib (Zelboraf), were among the top breakthroughs in cancer research in 2011.

Radiotherapy often results in the loss of some salivary gland function, causing hyposalivation and xerostomia.

Inhibiting the RANKL protein, which is involved in bone metabolism, can delay the onset of the bone metastases in men with castration-resistant prostate cancer.